Oncology Central

Keytruda® delivers survival success in pivotal KEYNOTE-407 lung cancer trial

Merck (NJ, USA) has announced that Keytruda® (pembrolizumab) has significantly improved overall survival (OS) and progression-free survival, in combination with carboplatin-paclitaxel or nab-paclitaxel, as a first-line treatment for squamous non-small cell lung cancer (NSCLC) in the pivotal Phase III KEYNOTE-407 trial.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.